Want to see RXRX full AI Analyst Report?
RXRX Stock Chart & Stats
$3.56
-$0.05(-1.66%)
At close: 4:00 PM EDT
$3.56
-$0.05(-1.66%)
Day’s Range― - ―
52-Week Range$2.77 - $7.18
Previous CloseN/A
Volume16.53M
Average Volume (3M)27.01M
Market Cap
$1.86B
Enterprise Value$1.47B
Total Cash (Recent Filing)$545.68M
Total Debt (Recent Filing)$61.88M
Price to Earnings (P/E)―
Beta3.16
Next Earnings
Nov 11, 2026EPS Estimate
-0.22Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.04
Shares Outstanding535,342,160
10 Day Avg. Volume41,095,398
30 Day Avg. Volume27,013,329
Financial Highlights & Ratios
PEG Ratio0.19
Price to Book (P/B)1.62
Price to Sales (P/S)24.50
P/FCF Ratio-4.84
Enterprise Value/Market Cap0.79
Enterprise Value/Revenue26.79
Enterprise Value/Gross Profit-57.42
Enterprise Value/Ebitda-3.31
Forecast
1Y Price Target
$6.63Price Target Upside86.33% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
EPS Forecast (FY)-0.9
Revenue Forecast (FY)$44.33M
Bulls Say, Bears Say
Bulls Say
AI Platform And Discovery EfficiencyRecursion’s proprietary multimodal data and integrated AI-plus-lab workflow are demonstrated at substantial scale, while reported design efficiency exceeds industry benchmarks. If repeatable, this can shorten discovery cycles, reduce research intensity, and support a differentiated platform for internal and partnered programs.
Partnering MonetizationPartner validation is translating the discovery platform into upfront and milestone cash, while Sanofi funds and leads future development of the optioned candidate. Additional milestones and potential royalties create a durable external funding and commercialization pathway beyond Recursion’s internal pipeline.
Clinical Pipeline ProgressREC-4881 provides an encouraging clinical proof point in a disease area described as having no approved therapies, with responses persisting after treatment interruption and a generally manageable safety profile. Further development could establish a meaningful internal product opportunity if regulatory discussions progress.
Bears Say
Persistent Losses And Cash BurnThe company remains structurally dependent on financing and partnering because revenue is declining, gross profit is negative, and cash outflows are substantial. Continued losses reduce financial flexibility and require successful pipeline execution or recurring external capital to sustain research and clinical development.
Equity Dilution From Capital RaiseThe large equity offering supplies capital for operations and clinical programs but increases the share base and demonstrates continued reliance on external funding. For existing holders, repeated raises can dilute ownership and may remain necessary while the company has not reached self-funding profitability.
Clinical And Regulatory UncertaintyImportant value creation milestones remain dependent on early clinical results, regulatory agreement, and eventual confirmatory outcomes. REC-4881’s encouraging data are not yet proof of registration, while later readouts may arrive after current runway timing, increasing execution and funding risk.
Recursion Pharmaceuticals News
RXRX FAQ
What was Recursion Pharmaceuticals’s price range in the past 12 months?
Recursion Pharmaceuticals lowest stock price was $2.77 and its highest was $7.18 in the past 12 months.
What is Recursion Pharmaceuticals’s market cap?
Recursion Pharmaceuticals’s market cap is $1.86B.
When is Recursion Pharmaceuticals’s upcoming earnings report date?
Recursion Pharmaceuticals’s upcoming earnings report date is Nov 11, 2026 which is in 23 days.
How were Recursion Pharmaceuticals’s earnings last quarter?
Recursion Pharmaceuticals released its earnings results on Aug 05, 2026. The company reported -$0.25 earnings per share for the quarter, missing the consensus estimate of -$0.24 by -$0.01.
Is Recursion Pharmaceuticals overvalued?
According to Wall Street analysts Recursion Pharmaceuticals’s price is currently Undervalued.
Does Recursion Pharmaceuticals pay dividends?
Recursion Pharmaceuticals does not currently pay dividends.
What is Recursion Pharmaceuticals’s EPS estimate?
Recursion Pharmaceuticals’s EPS estimate is -0.22.
How many shares outstanding does Recursion Pharmaceuticals have?
Recursion Pharmaceuticals has 535,342,160 shares outstanding.
What happened to Recursion Pharmaceuticals’s price movement after its last earnings report?
Recursion Pharmaceuticals reported an EPS of -$0.25 in its last earnings report, missing expectations of -$0.24. Following the earnings report the stock price went down -4.23%.
Which hedge fund is a major shareholder of Recursion Pharmaceuticals?
Currently, no hedge funds are holding shares in RXRX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Recursion Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$6.63 (86.33% Upside)
$6.63 (86.33% Upside)
Blogger Sentiment
Neutral
RXRX Sentiment 50%
Sector Average 67%
Sector Average 67%
Hedge Fund Trend
Increased
By 1.2M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $125.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 0.6%
Last 30 Days ▲ 1.7%
Last 30 Days ▲ 1.7%
News Sentiment
Very Bullish
Bullish news 89%
Bearish news 11%
Bearish news 11%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-45.51%
12-Months-Change
Fundamentals
Return on Equity
-50.41%
Trailing 12-Months
Asset Growth
-6.89%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Recursion Pharmaceuticals
Recursion Pharmaceuticals, Inc. operates as a biotechnology firm currently in its clinical development phase. The company's mission is to revolutionize drug discovery by decoding biological processes, utilizing an integrated approach that combines technological innovations across biology, chemistry, automation, data science, and engineering. Their developmental pipeline features several clinical-stage compounds: REC-994, which is advancing through Phase IIa trials for cerebral cavernous malformation; REC-3599, currently in Phase I trials for GM2 gangliosidosis; REC-2282, aimed at treating neurofibromatosis type 2; and REC-4881, intended for familial adenomatous polyposis. Beyond these, Recursion maintains a comprehensive preclinical portfolio. This includes REC-3964 for Clostridium difficile colitis, REC-64917 targeting neural or systemic inflammation, and REC-65029 for HRD-negative ovarian cancer. Further preclinical candidates are REC-648918, designed to enhance anti-tumor immunity; REC-2029 for wnt-mutant hepatocellular carcinoma; REC-14221 for various solid and hematological malignancies; and REC-64151, focused on addressing immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has established strategic collaborations and agreements with partners such as Bayer AG, the University of Utah Research Foundation, the Ohio State Innovation Foundation, Chromaderm, Inc., and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Salt Lake City, Utah.
RXRX Company Deck
RXRX Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presents a strong set of operational and technical highlights: multiple advancing clinical programs with compelling early efficacy (REC-4881), a cleared IND for a precision-selective oncology candidate (REC-7735), large proprietary data assets (>50 PB, massive cellular atlases), meaningful partnership cash inflows (> $500M realized, > $260M from Roche-Genentech) and demonstrated efficiency gains in design speed and operating costs (guidance lowered to $375M, ~40% reduction vs 2024 pro forma). Key risks and lowlights are typical for a clinical-stage biotech: regulatory and clinical uncertainty in rare disease and CNS programs, timing of pivotal data (some milestones extend beyond the current cash runway), competitive pressure as AI tools proliferate, and the early-stage nature of some proofs. Overall, positive operational momentum and external validation from partners outweigh the remaining clinical and market risks, but the company still faces execution and timing risks as programs advance.View all RXRX earnings summariesRXRX Stock 12 Month Forecast
Average Price Target
$6.63
▲(86.33% Upside)
Technical Analysis
Denali Therapeutics
―
Nurix Therapeutics
―
Monte Rosa Therapeutics
―
AbSci
―
Generate Biomedicines, Inc.
―
Ownership Overview
2.87% Insiders
12.72% Mutual Funds
0.10% Other Institutional Investors
51.45% Public Companies and Individual Investors